<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02917200</url>
  </required_header>
  <id_info>
    <org_study_id>DAV132-CL-1004</org_study_id>
    <secondary_id>2015-A01899-40</secondary_id>
    <nct_id>NCT02917200</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Different DAV132 Dose Regimens in Healthy Volunteers</brief_title>
  <official_title>Impact of Different DAV132 Dose Regimens (From 2 to 22.5 g/Day During 7 Days, Bid and Tid) on the Fecal Moxifloxacin Concentrations and the Intestinal Microbiota of Healthy Volunteers Treated With Moxifloxacin 400 mg/Day During 5 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Da Volterra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Da Volterra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether different DAV132 dose regimens are safe and&#xD;
      effective for capturing fecal residues of moxifloxacin in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate the performances of different DAV132 dose regimens in&#xD;
      healthy volunteers:&#xD;
&#xD;
        -  To capture antibiotic residues in the colon without interfering with its systemic&#xD;
           pharmacokinetics.&#xD;
&#xD;
        -  To prevent antibiotic-induced changes of the intestinal microbiota. In addition, the&#xD;
           security of DAV132 given at different dose regimens during 7 days will be evaluated.&#xD;
&#xD;
      This is a prospective, randomized, controlled, repeated doses, 12 parallel groups, open-label&#xD;
      study, blinded to analytical and microbiological evaluations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2016</start_date>
  <completion_date type="Actual">December 2, 2016</completion_date>
  <primary_completion_date type="Actual">December 2, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of free moxifloxacin fecal concentrations from D1 to D16 (AUC D1-D16)</measure>
    <time_frame>over 16 days after treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacterial diversity of the intestinal microbiota (16S rDNA profiling)</measure>
    <time_frame>over 37 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of moxifloxacin plasma concentrations from 0 to 24 hours (AUC0-24h) on D1 and D5</measure>
    <time_frame>over 5 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum moxifloxacin plasma concentrations (Cmax) on D1 and D5</measure>
    <time_frame>over 5 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and percentage of subjects with at least one adverse event</measure>
    <time_frame>over 37 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with samples positive for treatment-emergent quinolone / fluoroquinolone-resistant Enterobacteriaceae</measure>
    <time_frame>over 37 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Clostridium difficile infection, evaluated by identification of C. difficile in diarrheic stools</measure>
    <time_frame>over 37 days after treatment start</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>MOX + CTRL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOX + DAV132 7.5 g tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOX + DAV132 7.5 g bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOX + DAV132 5 g tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOX + DAV132 5 g bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOX + DAV132 3.3 g tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOX + DAV132 3 g bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOX + DAV132 2 g tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOX + DAV132 1.5 g bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOX + DAV132 1 g tid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOX + DAV132 1 g bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTRL</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Negative control, tid, 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Oral route</description>
    <arm_group_label>MOX + CTRL</arm_group_label>
    <arm_group_label>MOX + DAV132 1 g bid</arm_group_label>
    <arm_group_label>MOX + DAV132 1 g tid</arm_group_label>
    <arm_group_label>MOX + DAV132 1.5 g bid</arm_group_label>
    <arm_group_label>MOX + DAV132 2 g tid</arm_group_label>
    <arm_group_label>MOX + DAV132 3 g bid</arm_group_label>
    <arm_group_label>MOX + DAV132 3.3 g tid</arm_group_label>
    <arm_group_label>MOX + DAV132 5 g bid</arm_group_label>
    <arm_group_label>MOX + DAV132 5 g tid</arm_group_label>
    <arm_group_label>MOX + DAV132 7.5 g bid</arm_group_label>
    <arm_group_label>MOX + DAV132 7.5 g tid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DAV132</intervention_name>
    <description>Oral route</description>
    <arm_group_label>MOX + DAV132 1 g bid</arm_group_label>
    <arm_group_label>MOX + DAV132 1 g tid</arm_group_label>
    <arm_group_label>MOX + DAV132 1.5 g bid</arm_group_label>
    <arm_group_label>MOX + DAV132 2 g tid</arm_group_label>
    <arm_group_label>MOX + DAV132 3 g bid</arm_group_label>
    <arm_group_label>MOX + DAV132 3.3 g tid</arm_group_label>
    <arm_group_label>MOX + DAV132 5 g bid</arm_group_label>
    <arm_group_label>MOX + DAV132 5 g tid</arm_group_label>
    <arm_group_label>MOX + DAV132 7.5 g bid</arm_group_label>
    <arm_group_label>MOX + DAV132 7.5 g tid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Negative control</intervention_name>
    <description>Oral route</description>
    <arm_group_label>CTRL</arm_group_label>
    <arm_group_label>MOX + CTRL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults (males and females), able to read and write, aged from 18 to 60 years&#xD;
             old inclusive.&#xD;
&#xD;
          2. Body mass index (BMI) 18.5 - 30 kg/m² inclusive.&#xD;
&#xD;
          3. Considered as healthy individuals according to a comprehensive clinical assessment&#xD;
             (detailed medical history and full physical examination).&#xD;
&#xD;
          4. Normal vital signs after 10-min rest in supine position: systolic blood pressure 95 -&#xD;
             140 mmHg inclusive, diastolic blood pressure 45 - 90 mmHg inclusive and heart rate&#xD;
             (pulse rate) 50 - 100 bpm inclusive. Out of range values can be accepted if judged&#xD;
             clinically non relevant by the Investigator.&#xD;
&#xD;
          5. Normal 12-lead ECG after 10-min rest in supine position: PR interval 120 - 220 msec&#xD;
             exclusive, QRS complex &lt;120 msec, and QT interval &lt;430 msec if male or &lt;450 msec if&#xD;
             female.&#xD;
&#xD;
          6. Normal hematology and blood biochemistry test results. Out of range values can be&#xD;
             accepted if judged clinically non relevant by the Investigator excepted for potassium&#xD;
             and magnesium for which normal values are required.&#xD;
&#xD;
          7. Normal digestive transit, with at least one daily stool.&#xD;
&#xD;
          8. Females participating in the study:&#xD;
&#xD;
               -  either must be of non-child bearing potential (surgically sterilized at least 3&#xD;
                  months prior to inclusion, or postmenopausal). Menopause is defined as being over&#xD;
                  60 years of age, or between 45 and 60 years of age and being amenorrheic for at&#xD;
                  least 2 years with plasma FSH levels &gt;30 IU/L;&#xD;
&#xD;
               -  or must have a negative pregnancy test and be not breastfeeding at screening, and&#xD;
                  must use abstinence or a double contraception method during the treatment period&#xD;
                  and for an additional period of 2 weeks after the end of investigational&#xD;
                  treatment. The accepted double contraception methods include the use of a highly&#xD;
                  effective method of birth control (intrauterine device or hormonal contraception)&#xD;
                  in addition to one of the following contraceptive options: (1) condom, (2)&#xD;
                  diaphragm or cervical/vault cap, (3) spermicide.&#xD;
&#xD;
          9. Having given and signed the written study informed consent prior to undertake any&#xD;
             study-related procedure.&#xD;
&#xD;
         10. Covered by the French health insurance system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Criteria related to the healthy status&#xD;
&#xD;
          1. Any history or presence of clinically relevant cardiovascular, pulmonary,&#xD;
             gastrointestinal, hepatic, renal, metabolic, hematological, neurological, bone and&#xD;
             joint, muscular, psychiatric, systemic, ocular, gynecologic (if female), or infectious&#xD;
             disease; or signs of acute illness.&#xD;
&#xD;
          2. Any history of relevant gastrointestinal disorders within three months prior to&#xD;
             inclusion.&#xD;
&#xD;
          3. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for each event,&#xD;
             more than twice a month). Subject suffering from migraine on D1 will be excluded.&#xD;
&#xD;
          4. Presence or history of drug hypersensitivity, or allergic disease diagnosed and&#xD;
             treated by a physician.&#xD;
&#xD;
             Criteria specific to the study&#xD;
&#xD;
          5. Contraindications to fluoroquinolones, or risk factors for adverse effects associated&#xD;
             to fluoroquinolones as defined in the moxifloxacin Summary of Product Characteristics,&#xD;
             and other than those already included into the inclusion/exclusion criteria: known&#xD;
             hypersensitivity to fluoroquinolones, history of tendinopathy associated with&#xD;
             fluoroquinolones, risk factor for tendinopathy / known tendon disorder, pregnancy,&#xD;
             breast feeding, known history of myasthenia gravis, known history of / risk factors&#xD;
             for QT interval prolongation (including close family history of arrhythmic disorders).&#xD;
             Subjects with a family history of, or actual glucose-6-phosphate dehydrogenase (G6PDH)&#xD;
             deficiency should be excluded. Subjects with rare hereditary problems of galactose&#xD;
             intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should be&#xD;
             excluded.&#xD;
&#xD;
          6. Contraindications to charcoal, or risk factors for adverse events associated to&#xD;
             charcoal other than those already included into the inclusion/exclusion criteria:&#xD;
             known hypersensitivity to charcoal, risk of gastrointestinal obstruction, perforation&#xD;
             or hemorrhage, recent digestive tract surgery.&#xD;
&#xD;
          7. Fecal colonization by C. difficile.&#xD;
&#xD;
          8. Recent history of hospitalization (within the last 3 months).&#xD;
&#xD;
          9. Any antibiotic administration within the last 3 months.&#xD;
&#xD;
         10. Any vaccination within the last 28 days.&#xD;
&#xD;
         11. Blood donation, regardless of the volume, within 2 months before inclusion and during&#xD;
             the study.&#xD;
&#xD;
         12. Any previous administration of medication and any previous intake of herbal products&#xD;
             known to interfere with drug metabolism such as St John's Wort within the last 14&#xD;
             days, with the exception of hormonal contraception or menopausal hormone replacement&#xD;
             therapy or paracetamol.&#xD;
&#xD;
             Criteria associated with addiction&#xD;
&#xD;
         13. History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per&#xD;
             day).&#xD;
&#xD;
         14. Smoking more than 5 cigarettes or equivalent per day (including nicotine-delivering&#xD;
             devices such as patches, gums and electronic cigarettes), unable to stop smoking&#xD;
             during the study.&#xD;
&#xD;
         15. Excessive consumption of beverages containing xanthine bases (more than 4 cups or&#xD;
             glasses per day).&#xD;
&#xD;
         16. Positive result on urine drug screen (amphetamines / methamphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine, opiates).&#xD;
&#xD;
         17. Positive alcohol test. Administrative criteria&#xD;
&#xD;
         18. Any subject who, in the judgment of the Investigator, is likely to be noncompliant&#xD;
             during the study, or unable to cooperate because of a language problem or poor mental&#xD;
             development.&#xD;
&#xD;
         19. Any subject in the exclusion period of a previous biomedical research according to&#xD;
             national law, and participation to any other clinical trial simultaneously.&#xD;
&#xD;
         20. Any subject who cannot be contacted in case of emergency.&#xD;
&#xD;
         21. Any subject who belongs to the Investigating Center staff.&#xD;
&#xD;
         22. Subject of legal age unable to give consent&#xD;
&#xD;
         23. Subject deprived of liberty by judicial or administrative decision&#xD;
&#xD;
         24. Subject of legal age under legal protection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Donazzolo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eurofins Optimed</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gières</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

